Norris Perne & French’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-221,424
Closed -$7.55M 163
2021
Q4
$7.55M Sell
221,424
-1,446
-0.6% -$56.6K 0.59% 65
2021
Q3
$10.8M Buy
222,870
+5,043
+2% +$233K 0.92% 51
2021
Q2
$9.84M Buy
217,827
+8,946
+4% +$396K 0.85% 56
2021
Q1
$10.1M Sell
208,881
-52,800
-20% -$2.75M 0.93% 49
2020
Q4
$14.1M Sell
261,681
-113,451
-30% -$5.13M 1.33% 32
2020
Q3
$13.8M Sell
375,132
-79,947
-18% -$2.97M 1.5% 28
2020
Q2
$14.1M Buy
455,079
+117,882
+35% +$3.27M 1.72% 25
2020
Q1
$9.31M Sell
337,197
-4,447
-1% -$133K 1.4% 35
2019
Q4
$9.97M Buy
341,644
+5,622
+2% +$134K 1.19% 44
2019
Q3
$6.47M Sell
336,022
-5,548
-2% -$130K 0.81% 53
2019
Q2
$7.49M Sell
341,570
-1,059
-0.3% -$23.2K 0.95% 49
2019
Q1
$7M Buy
342,629
+6,051
+2% +$105K 0.92% 51
2018
Q4
$4.27M Buy
336,578
+436
+0.1% +$6.5K 0.67% 57
2018
Q3
$5.15M Buy
+336,142
New +$4.65M 0.67% 56

Other funds holding NEO

Norris Perne & French's NEO Position: Q1 2022 in Review

Norris Perne & French sold out of NeoGenomics (NEO) in Q1 2022, closing a stake of 221,424 shares — an estimated $7.55M sold.

Norris Perne & French first reported a position in NEO in Q3 2018 and held it in 14 quarters. The position peaked at $14.1M in Q2 2020. 280 funds tracked by Wall St. Rank hold NEO as of Q1 2022.

  • Norris Perne & French reported no remaining NeoGenomics position as of Q1 2022 after selling out during the quarter.
  • Norris Perne & French sold 221,424 NeoGenomics shares in Q1 2022, an estimated $7.55M.
  • Norris Perne & French first reported a position in NeoGenomics in Q3 2018 and held it in 14 quarters.
  • Norris Perne & French's NeoGenomics position peaked at $14.1M in Q2 2020.
  • 280 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2022.

Based on Norris Perne & French's 13F filing for Q1 2022, filed 26 Apr 2022.